Sema4 Looks to M&A After Successful SPACSema4 Looks to M&A After Successful SPAC

The company is set to acquire Opko Health’s subsidiary, GeneDx for $623 million.

Omar Ford

January 19, 2022

1 Min Read
M&A
Image by: Panther Media GmbH / Alamy Stock Photo

Sema4 is acquiring Opko Health’s subsidiary, GeneDx, in a deal that could have a price tag of $623 million if milestones are added in. The acquisition is set to close in 2Q22.

The combined company could have $350 million in pro forma 2022 revenue. GeneDx specializes in rare disease diagnostic and exome sequencing services.

The Gaithersburg, MD-based company brings more than 300,000 clinical exomes and more than 2.1 million annotated phenotypes to strengthen Sema4’s 12 million de-identified clinical records for Centrellis, a health intelligence platform, and Traversa, its genomic analysis platform for optimizing health screenings.

“This acquisition gives us the opportunity to accelerate the use of genomics as standard of care by providing a deeper menu of precision medicine solutions to our health system partners to better meet their clinical needs,” said Eric Schadt, PhD, Founder and CEO of Sema4. “Adding GeneDx’s comprehensive dataset and capabilities to our offerings enables us to inform on an even broader range of diseases, further closing the gap between the practice of medicine and the availability of more clinically actionable guidance. GeneDx’s operational prowess and market-leading cost structure in exome and genome sequencing will also help accelerate our path to improved gross margins and profitability.”

 The acquisition comes less than a year after Sema4 went public through a nearly special purpose acquisition corporation merger with CM Life Sciences.

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like